Professor, Department of Pharmacology, Yale University
1968 BS Chemistry, Antioch College
1974 PhD Biochemistry, Brandeis University
Postdoctoral training with HR Kaback at the Roche Institute of Molecular Biology
American Heart Association Established Investigator
1995-2004 Editorial Advisory Board Member, Biochemistry
2004-present Editorial Board, Journal of Biological Chemistry
Our research concerns the proteins involved in neurotransmitter recycling responsible for the reuptake of serotonin and other biogenic amines. We are interested in how the structure of these proteins determines their ability to couple ion gradients to substrate transport. The transporters are responsible for the process that terminates the action of serotonin, norepinephrine, and dopamine released into the synaptic cleft. They are targets for antidepressant drugs like fluoxetine (Prozac) and for stimulants such as cocaine and amphetamines, such as MDMA (ecstasy). Current efforts in the laboratory include the identification of the pathway by which serotonin passes through the membrane, including residues that are involved in substrate and inhibitor binding and those involved in conformational changes that accompany transport. We are also studying the regulation of serotonin transporter activity by phosphorylation, and we are investigating bacterial homologues of the neurotransmitter transporter family for insights into the structure of these proteins.
In the role of Faculty Member, Gary Rudnick contributes recommendations and reviews to the Neuronal Signaling Mechanisms Section in the Neuroscience Faculty, writing brief accessible comments to summarize the value of the articles and adding rating score.
The Faculty comprises Heads of Faculty, Heads of Section, Faculty Members and Associate Faculty Members, as well as an International Advisory Board.
Read more about F1000Prime »